利用循环肿瘤DNA预测和监测III期黑色素瘤的复发
在133例已切除III期黑色素瘤患者中,99例(74%)通过肿瘤组织测序确定体细胞突变,用个体化微滴数字PCR检测315份前瞻性收集的血浆样本。基线及术后ctDNA检测均与更差的无复发生存和远处无转移生存相关,并在独立队列(n=29)中验证。
要点
- 在未接受辅助治疗的81例患者中,基线ctDNA阳性者90%、术后ctDNA阳性者100%在中位随访20个月时复发。
- 基线ctDNA检测预测无复发生存(HR 2.9;95%CI 1.5-5.6;P=0.002),术后检测HR 10(95%CI 4.3-24;P<0.001)。
- 基线及术后ctDNA检测均与更差远处无转移生存相关,并在独立队列中验证。
核心结论
- 在两个独立前瞻性队列中,基线和术后ctDNA检测可识别复发风险最高的III期黑色素瘤患者,并可能为辅助治疗决策提供信息。
研究设计与样本
- 研究纳入133例已切除III期黑色素瘤患者,其中99例(74%)通过肿瘤组织测序确定体细胞突变,并使用个体化微滴数字PCR(ddPCR)检测315份前瞻性收集的血浆样本。
- 外部验证在独立前瞻性队列(n=29)中进行。
主要发现
- 在99例突变阳性患者中,37例(37%)检测到ctDNA。
- 在81例未接受辅助治疗的患者中,基线ctDNA检测阳性者90%复发,术后时间点ctDNA检测阳性者100%复发,中位随访20个月。
- 基线ctDNA检测预测无复发生存(RFS)风险(HR 2.9;95%CI 1.5-5.6;P=0.002),术后检测HR 10(95%CI 4.3-24;P<0.001)。
- 基线ctDNA检测与更差远处无转移生存(DMFS)相关(HR 2.9;95%CI 1.3-5.7;P=0.003),术后检测HR 11(95%CI 4.3-27;P<0.001)。
- 在多变量分析中调整疾病分期和BRAF突变状态后,ctDNA检测仍是无复发生存和远处无转移生存的独立预测因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The advent of effective adjuvant therapies for patients with resected melanoma has highlighted the need to stratify patients based on risk of relapse given the cost and toxicities associated with treatment. Here we assessed circulating tumor DNA (ctDNA) to predict and monitor relapse in resected stage III melanoma. PATIENTS AND METHODS: Somatic mutations were identified in 99/133 (74%) patients through tumor tissue sequencing. Personalized droplet digital PCR (ddPCR) assays were used to detect known mutations in 315 prospectively collected plasma samples from mutation-positive patients. External validation was performed in a prospective independent cohort (n = 29). RESULTS: ctDNA was detected in 37 of 99 (37%) individuals. In 81 patients who did not receive adjuvant therapy, 90% of patients with ctDNA detected at baseline and 100% of patients with ctDNA detected at the postoperative timepoint relapsed at a median follow up of 20 months. ctDNA detection predicted patients at high risk of relapse at baseline [relapse-free survival (RFS) hazard ratio (HR) 2.9; 95% confidence interval (CI) 1.5-5.6; P = 0.002] and postoperatively (HR 10; 95% CI 4.3-24; P < 0.001). ctDNA detection at baseline [HR 2.9; 95% CI 1.3-5.7; P = 0.003 and postoperatively (HR 11; 95% CI 4.3-27; P < 0.001] was also associated with inferior distant metastasis-free survival (DMFS). These findings were validated in the independent cohort. ctDNA detection remained an independent predictor of RFS and DMFS in multivariate analyses after adjustment for disease stage and BRAF mutation status. CONCLUSION: Baseline and postoperative ctDNA detection in two independent prospective cohorts identified stage III melanoma patients at highest risk of relapse and has potential to inform adjuvant therapy decisions.
引用
- Tan L, Sandhu S, Lee RJ, et al. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Ann Oncol. 2019. PMID: 30838379. doi:10.1093/annonc/mdz048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。